Trial Profile
a Phase 1, Open-Label, Single Dose, Relative Bioavailability Study In Healthy Volunteers Comparing PF-04958242 Capsule Formulation To PF-04958242 Oral Solution In The Fasted State
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Nov 2019
Price :
$35
*
At a glance
- Drugs Pesampator (Primary)
- Indications Cognition disorders
- Focus Pharmacokinetics
- Sponsors Pfizer
- 18 Nov 2026 In March 2018, Biogen acquired BIIB 104 (previously known as PF 4958242) from Pfizer. Study was completed in 17 Dec 2012. So I have retained sponsor Pfizer.
- 25 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Jul 2012 New trial record